Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gold sodium thiomalate is a disease-modifying antirheumatic drug (DMARD) and a gold compound used primarily as an adjunctive treatment for active rheumatoid arthritis in both adults and children. It is administered by intramuscular injection. The drug exerts immunosuppressive and anti-inflammatory effects, though its precise mechanism of action remains unclear. Evidence suggests it may decrease prostaglandin synthesis or alter cellular mechanisms by inhibiting sulfhydryl systems[5][7]. Gold accumulates in synovial cells, leading to dose-dependent inhibition of cell proliferation and protein synthesis, particularly collagen production[6][8]. This suppresses synovitis and slows the progression of joint damage but does not repair existing cartilage or bone damage[1][2][3]. Gold sodium thiomalate is most effective during early active stages of rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gold sodium thiomalate.